Daily BriefsThematic (Sector/Industry)

Daily Brief Thematic (Sector/Industry): Ohayo Japan | Fed Minutes Signal September Rate Cut and more

In today’s briefing:

  • Ohayo Japan | Fed Minutes Signal September Rate Cut
  • Could a Japan “Megaquake” Disrupt Semis?
  • Japan Morning Connection: Mercari, Sumitomo Forestry, Anritsu
  • What Does a Trump Presidency Mean for China Healthcare?


Ohayo Japan | Fed Minutes Signal September Rate Cut

By Mark Chadwick

  • Stocks edged higher Wednesday after Federal Reserve minutes strengthened expectations for a September rate cut
  • Japan set a record for foreign visitors in July, with 3.29 million arrivals, driven by a weak yen and summer holiday
  • Japan Tobacco (JT) announced a $2.4 billion acquisition of Vector Group, the fourth-largest U.S. tobacco company

Could a Japan “Megaquake” Disrupt Semis?

By Jim Handy

  • Japan’s Meteorological Agency has issued a warning of an upcoming serious 8-9-point earthquake
  • The expected epicenter is home to at least one dozen semiconductor wafer fabrication plants: “Fabs”
  • While it’s hard to predict earthquakes, this news should be considered when investing in the area.

Japan Morning Connection: Mercari, Sumitomo Forestry, Anritsu

By Andrew Jackson

  • Good retailer numbers and outlooks by Target and TJX setting a positive tone for the likes of Mercari on the read for consumer spending.
  • Toll Bros numbers from the day before lifting US Homebuilders should see the likes of Sumitomo Forestry rebound off yesterdays weak price action.
  • Japanese R/E names look increasingly vulnerable to downside ahead of Ueda’s speech tomorrow which should point to a BoJ trajectory for future rate hikes.

What Does a Trump Presidency Mean for China Healthcare?

By Xinyao (Criss) Wang

  • The assassination of Trump in July has greatly increased the probability of his election as president this year. However, a Trump presidency is not necessarily good for healthcare industry.
  • Trump’s reform in the field of healthcare has two major propositions – One is to achieve the independence of US pharmaceutical supply chain. The other is to reduce drug prices.
  • From a US national security perspective, China’s APIs/CXO would be the segments with the highest sanction risk. China Biotech may also face some headwinds. The risk of “decoupling” further increases.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars